表紙
市場調査レポート

非アルコール性脂肪性肝炎:治療薬パイプライン分析および2016年までの市場予測

Nonalcoholic Steatohepatitis - Drug Pipeline Analysis and Market Forecasts to 2016

発行 GlobalData 商品コード 118638
出版日 ページ情報 英文 54 Pages
即納可能
価格
こちらの商品の販売は終了いたしました。
Back to Top
非アルコール性脂肪性肝炎:治療薬パイプライン分析および2016年までの市場予測 Nonalcoholic Steatohepatitis - Drug Pipeline Analysis and Market Forecasts to 2016
出版日: 2010年04月15日 ページ情報: 英文 54 Pages

当商品の販売は、2016年07月01日を持ちまして終了しました。

概要

当レポートでは、非アルコール性脂肪性肝炎市場について治療薬パイプライン分析および2016年までの市場予測を行っており、市場の特徴をはじめ、競合、パイプラインなどを評価分析し、将来の市場競争、企業プロファイルを盛り込んで、概略以下の構成でお届けします。

第1章 目次

第2章 非アルコール性脂肪性肝炎市場:市場の特徴

  • 疾患の概要
  • 症状
  • 診断法
  • 処置
  • 疫学
  • 予防
  • 市場規模
  • 市場予測および年複利成長率(CAGR)
  • 市場促進および阻害要因
  • 機会およびアンメットニーズ
  • 要点

第3章 競合のアセスメント

  • 概要
  • 戦略的競合企業の評価
  • 主な市販製品のプロファイル
  • 要点

第4章 パイプラインのアセスメント

  • 概要
  • 戦略的パイプラインの評価
  • 治療:臨床開発中の有望な治療薬
  • 臨床開発中の有望な治療薬の分子プロファイル
  • 非アルコール性脂肪性肝炎治療市場:作用機序別臨床パイプライン
  • 非アルコール性脂肪性肝炎パイプライン:臨床開発段階別パイプライン
  • 中止・中断
  • 要点

第5章 将来の市場競争についての示唆

第6章 将来の企業

  • イントロダクション
  • Raptor Pharmaceuticals
  • Gilead Sciences
  • Eli Lilly and Company
  • Enzo Biochem.

第7章 付録

図表

目次
Product Code: GDHCPRT099

Summary

GlobalData' s report, “Nonalcoholic Steatohepatitis (NASH)- Drug Pipeline Analysis and Market Forecasts to 2016” is an essential source of information and analysis on the global nonalcoholic steatohepatitis market. The report identifies the key trends shaping and driving the global nonalcoholic steatohepatitis market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global nonalcoholic steatohepatitis sector. GlobalData estimated that the Nonalcoholic Steatohepatitis (NASH) market was worth $1.8 billion in 2009. The major reason for the limited market revenues is that there is no approved drug for the treatment of NASH. NASH is an unrecognized cause of cryptogenic cirrhosis with emerging importance. It is a more aggressive form of NAFLD (Nonalcoholic Fatty Liver Disease), which often progresses to liver cirrhosis. The increased prevalence of diabetes, obesity and hyperlipidemia are considered to be important causes of NASH. Antioxidants, anti-diabetic medications, anti-obesity medications and antihyperlipidemics are some of the off-label products currently used by NASH patients. The modest growth forecast is primarily attributed to a weak pipeline landscape. Due to the fact that low diagnosis rates, low prescription rates and low treatment seeking rates continue to pose significant challenges for prospective market entrants, the market landscape in future is expected to remain static without any significant dynamism.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData’s team of industry experts.

Scope

The scope of the report includes:
- Annualized global nonalcoholic steatohepatitis market revenue data from 2001 to 2009, forecast for seven years to 2016.
- Key geographies covered in this report include the US (the United States), the UK (the United Kingdom), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across the different phases of development by mechanism of action and emerging trends. The key classes of mechanism of action include dietary supplements, enzyme inhibitors, PPAR (peroxisome proliferator-activated receptor) gamma selective agonists, combination therapies, cholesterol Inhibitors, CB-1 cannabinoid receptor antagonists, angiotensin II receptor antagonists, lipid peroxidation inhibitors, glutathione enhancers and immunologic drugs.
- Analysis of the current and future market competition in the global nonalcoholic steatohepatitis market. Key market players covered are Raptor Pharmaceuticals, Gilead Sciences, Axcan Pharma, Eli Lilly & Company and Enzo Biochem.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the future market associated with NASH.

Reasons to buy

- Develop and design your in-licensing and out-licensing strategies through a review of the pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global NASH market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global NASH market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global NASH market landscape? - identify, understand and capitalize.

Table of Contents

1. Table of contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Nonalcoholic Steatohepatitis Market : Market Characterization

  • 2.1. Disease Overview
  • 2.2. Symptoms
  • 2.3. Diagnosis
    • 2.3.1. Ultrasonography
    • 2.3.2. Computed Tomography
    • 2.3.3. Magnetic Resonance Imaging
    • 2.3.4. Liver function tests
    • 2.3.5. Liver Biopsy
  • 2.4. Treatment
  • 2.5. Epidemiology
  • 2.6. Prevention
  • 2.7. Nonalcoholic Steatohepatitis Disease Market Size
  • 2.8. Nonalcoholic Steatohepatitis Market Forecast and CAGR
  • 2.9. Drivers and Barriers for the Nonalcoholic Steatohepatitis Disease Market
    • 2.9.1. Drivers for the NASH Market
    • 2.9.2. Barriers for the NASH Market
  • 2.10. Opportunity and Unmet Need
  • 2.11. Key Takeaway

3. Nonalcoholic Steatohepatitis Market : Competitive Assessment

  • 3.1. Overview
  • 3.2. Strategic Competitor Assessment
  • 3.3. Product Profile for the Major Off-Label Marketed Products in the Nonalcoholic Steatohepatitis Market
    • 3.3.1. Antioxidants
    • 3.3.2. Anti-diabetic Medications
    • 3.3.3. Anti-obesity Medications
    • 3.3.4. Antifibrotic Medications
  • 3.4. Key Takeaway

4. Nonalcoholic Steatohepatitis Market : Pipeline Assessment

  • 4.1. Overview
  • 4.2. Strategic Pipeline Assessment
    • 4.2.1. Technology Trends Analytic Framework
  • 4.3. Nonalcoholic Steatohepatitis Therapeutics - Promising Drugs under Clinical Development
  • 4.4. Molecule Profile for Promising Drugs under Clinical Development
    • 4.4.1. DR Cysteamine (delayed release cysteamine bitartrate)
    • 4.4.2. GS 9450 (LB84451)
    • 4.4.3. High-Dose Ursodesoxycholic acid (HD-UDCA)
    • 4.4.4. Byetta (exenatide)
    • 4.4.5. EGS21 (beta glucosylceramide formulation)
  • 4.5. Nonalcoholic Steatohepatitis Market - Clinical Pipeline by Mechanism of Action
  • 4.6. Nonalcoholic Steatohepatitis - Pipeline by Clinical Phases of Development
    • 4.6.1. Nonalcoholic Steatohepatitis Therapeutics - Phase III Clinical Pipeline
    • 4.6.2. Nonalcoholic Steatohepatitis Therapeutics - Phase II Clinical Pipeline
    • 4.6.3. Nonalcoholic Steatohepatitis Therapeutics - Phase I Pipeline
    • 4.6.4. Nonalcoholic Steatohepatitis Therapeutics - Preclinical Pipeline
  • 4.7. Discontinued Drug for Nonalcoholic Steatohepatitis Disease
  • 4.8. Key Takeaway

5. Nonalcoholic Steatohepatitis Market : Implications for Future Market Competition

6. Nonalcoholic Steatohepatitis Disease Market : Future Players in the Nonalcoholic Steatohepatitis Market

  • 6.1. Introduction
  • 6.2. Raptor Pharmaceuticals
    • 6.2.1. Company Overview
    • 6.2.2. Gastroenterology Disease Portfolio
    • 6.2.3. Nonalcoholic Steatohepatitis Product Portfolio
  • 6.3. Gilead Sciences
    • 6.3.1. Company Overview
    • 6.3.2. Gastroenterology Disease Portfolio
    • 6.3.3. Nonalcoholic Steatohepatitis Product Portfolio
    • 6.3.4. Axcan Pharma
    • 6.3.5. Company Overview
    • 6.3.6. Gastroenterology Portfolio
    • 6.3.7. Nonalcoholic Steatohepatitis Product Portfolio
  • 6.4. Eli Lilly and Company
    • 6.4.1. Company Overview
    • 6.4.2. Gastroenterology Portfolio
    • 6.4.3. Nonalcoholic Steatohepatitis Product Portfolio
  • 6.5. Enzo Biochem
    • 6.5.1. Company Overview
    • 6.5.2. Gastroenterology Portfolio
    • 6.5.3. Nonalcoholic Steatohepatitis Product Portfolio

7. Nonalcoholic Steatohepatitis Market : Appendix

  • 7.1. Market Definitions
  • 7.2. Abbreviations
  • 7.3. Research Methodology
    • 7.3.1. Coverage
    • 7.3.2. Secondary Research
    • 7.3.3. Forecasting
    • 7.3.4. Primary Research
    • 7.3.5. Expert Panels
  • 7.4. Contact Us
  • 7.5. Disclaimer
  • 7.6. Sources

List of Tables

  • Table 1: Grading and Staging of Nonalcoholic Steatohepatitis, 2010
  • Table 2: Treatment Options For the Treatment of Nonalcoholic Steatohepatitis, 2010
  • Table 3: Prevalence of Liver Abnormalities Among Obese, Diabetic and General Population in the Western Countries, 2010
  • Table 4: Nonalcoholic Steatohepatitis Therapeutics, Global, Market Revenues ($m), 2001-2009
  • Table 5: Nonalcoholic Steatohepatitis Therapeutics, Global, Market Revenues ($m), 2009-2016
  • Table 6: Nonalcoholic Steatohepatitis Therapeutics - Most Promising Drugs Under Clinical Development, 2010
  • Table 7: Nonalcoholic Steatohepatitis Therapeutics - Phase III Clinical Pipeline, 2010
  • Table 8: Nonalcoholic Steatohepatitis Therapeutics - Phase II Clinical Pipeline, 2010
  • Table 9: Nonalcoholic Steatohepatitis Therapeutics - Phase I Pipeline, 2010
  • Table 10: Nonalcoholic Steatohepatitis Therapeutics - Preclinical Pipeline, 2010
  • Table 11: List of Discontinued Drugs for Nonalcoholic Steatohepatitis, 2010
  • Table 12: Raptor Pharmaceuticals - Pipeline Products, 2010
  • Table 13: Gilead Sciences- Pipeline Products, 2010
  • Table 14: Axcan Pharma - Marketed Products, 2010
  • Table 15: Axcan Pharma - Pipeline Products, 2010
  • Table 16: Eli Lilly and Company - Pipeline Products, 2010
  • Table 17: Enzo Biochem - Pipeline Products, 2010

List of Figures

  • Figure 1: Two-Hit Hypothesis of Disease Pathogenesis in Nonalcoholic Steatohepatitis, 2010
  • Figure 2: Risk Factors Associated with Nonalcoholic Steatohepatitis
  • Figure 3: Global Nonalcoholic Steatohepatitis Therapeutics Market Revenue ($m) 2001-2009
  • Figure 4: Global Nonalcoholic Steatohepatitis Therapeutics Market Revenue ($m) 2009-2016
  • Figure 5: Opportunity and Unmet Need in the Nonalcoholic Steatohepatitis Market, 2010
  • Figure 6: Strategic Competitor Assessment of the Major Off-Label Products for Nonalcoholic Steatohepatitis, 2010
  • Figure 7: Technology Trends Analytic Framework of the Nonalcoholic Steatohepatitis Pipeline, 2010
  • Figure 8: Technology Trends Analytic Framework of the Nonalcoholic Steatohepatitis Pipeline - Description, 2010
  • Figure 9: Nonalcoholic Steatohepatitis Market - Clinical Pipeline by Mechanism of Action, 2010
  • Figure 10: Nonalcoholic Steatohepatitis Pipeline by Phase of Clinical Development, 2010
  • Figure 11: Implications for Future Market Competition in the Nonalcoholic Steatohepatitis Market, 2010
  • Figure 12: Nonalcoholic Steatohepatitis Market - Clinical Pipeline by Company, 2010
  • Figure 13: GlobalData Methodology
  • Figure 14: GlobalData Market Forecasting Model
Back to Top